OJOTS  Vol.3 No.4 , November 2013
Allograft Survival without Immunosuppression in Landrace Pigs after 90 Days
Abstract: Allotransplantation is helpful in order to maintain the life in some cases, but immunosuppression causes collateral effects. In this study, we were reporting the results of allografts in Landrace pigs, which were implanted on collagen-generator devices. After 2 weeks of implantation, the devices were carried out to assess allograft viability at 30, 60 and 90 days post implant. The implanted cells were islets of Langerhans and the aim was to prove their presence by immunohistochemistry for insulin and glucagon. The results were positive at 30, 60 and 90 days post implant. It demonstrated that the collagen-generator device permits the cell viability without using anti-rejected drugs or immunomodulating cells.
Cite this paper: Valdés-Gonzalez, R. , Acevedo, A. , Rodriguez-Ventura, A. and Mayoral, P. (2013) Allograft Survival without Immunosuppression in Landrace Pigs after 90 Days. Open Journal of Organ Transplant Surgery, 3, 63-64. doi: 10.4236/ojots.2013.34012.

[1]   K. Takahashi, “A New Immunosuppressive Therapy in ABO Incompatible Kidney Transplantation Based on a New Concept of Accommodation,” International Congress Series, Vol. 1292, 2006, pp. 73-87.

[2]   R. A. Valdes-Gonzalez, L. M. Dorantes, G. N. Garibay, et al., “Xenotransplantation of Porcine Neonatal Islets of Langerhans and Sertoli Cells: A 4-Year Study,” European Journal of Endocrinology, Vol. 153, No. 3, 2006, pp. 419-427.

[3]   G. R. Rayat and R. G. Gill, “Indefinite survival of Neonatal Porcine Islet Xenografts by Simultaneous Targeting of LFA-1 and CD154 or CD45RB,” Diabetes, Vol. 54, No. 2, 2005, pp. 443-451.

[4]   D. Y. Lee, S. J. Park, S. Lee, J. H. Nam and Y. Byun, “Highly Poly(Ethylene) Glycolylated Islets Improve Long-Term Islet Allograft Survival without Immunosuppressive Medication,” Tissue Engineering, 2007 [Epub Ahead of Print].

[5]   C. N. Street, J. R. T. Lakey, A. M. J. Shapiro, et al., “Islet Graft Assessment in the Edmonton Protocol. Implications for Predicting Long-Term Clinical Outcome,” Diabetes, Vol. 53, No. 12, 2004, pp. 3107-3114.

[6]   C. G. Groth, O. Korsgren, A. Tibell, J. Tollemar, E. Moller, J. Bolinder, J. Ostman, F. P. Reinholt, C. Hellerstrom and A. Andersson, “Transplantation of Porcine Fetal Pancreas to Diabetic Patients,” The Lancet, Vol. 344, No. 8934, 1994, pp. 1402-1404.

[7]   A. Pileggi, R. D. Molano, C. Ricordi, E. Zahr, J. Collins, R. Valdes and L. Inverardi, “Reversal of Diabetes by Pancreatic Islet Transplantation into a Subcutaneous, Neovascularized Device,” Transplantation, Vol. 81, No. 9, 2006, pp. 1318-1324.